Novo Nordisk‘s ‘Wegovy‘ is the first-to-market in a new class of highly effective weight-loss drugs: used alongside changes to diet and exercise, it leads to an average weight loss of around 15%. Novo Nordisk has to convince European governments to pay for its obesity drug for the most overweight or those with co-morbidities: both the medical and cost benefits of the treatment are emphasized, because such people are often among those who consume the highest cost in healthcare systems.
Read more on Reuters.com
